Ocugen, Inc. (OCGN) Financial Articles

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited... Read More

Industry: Biotechnology Sector: Healthcare

Ocugen, Inc. (OCGN)

Entirely Uncomfortable See Alternatives

Business Score

Financial Score

ESG Score

Last updated: 2/2/2022

Report Summary

The business’s revenue primarily comes from Haram.
Interest is not used while running the company.
The company has a net negative impact on at least one of the following: environment, society or governance.

What are Halal Investors' Comfort Levels?

Our Comfort Levels are based on our analysts’ latest review of a company's business, finances, and Environmental, Social and Governance (ESG) Impact. Our reports are not meant to be understood as a religious ruling (fatwa). Rather, they represent our best efforts in trying to identify whether a company is engaged in anything forbidden in Islam (haram) and to what extent. Based on our analysis, we determine our Comfort Level with investing in the company. We encourage readers to let us know if we missed anything in the comments and to voice their agreement/disagreement by leaving a thumbs up/down. Read more about our methodology.

Loading Articles...

Ocugen, Inc. (OCGN) Financial Articles

Read the full report with business, financial, & ESG analysis

Members Only

What's included

Consider these free reports

Consider these instead

Get the latest reports & insights from Halal Investors. Sign up for our newsletter.